Global stability of age-of-infection multiscale HCV model with therapy

Xiaowen Xiong1, Yanqiu Li1, Bingliang Li1

  • 1School of Physical and Mathematical Sciences, Nanjing Tech University, Nanjing 211816, China.

In order to treat the diseases caused by hepatitis C virus (HCV) more efficiently, the concentration of HCV in blood, cells, tissues and the body has attracted widespread attention from related scholars. This paper studies a dynamic dependent HCV model (more specifically, including age structure and treatment methods model) that concludes states of infection-free and infected equilibrium. Through eigenvalue analysis and Volterra integral formula, it proves that $E_0$ is globally asymptotically stable when $\mathcal{R}<1$. After explaining the existence, uniqueness and positive properties of the solution of the system, we have proved the global asymptotic stability of $E^*$ when $\mathcal{R}>1$ by constructing a suitable Lyapunov function. Through the above proofs, it can be concluded that effective treatment measures can significantly reduce the number of HCVs, so many related researchers are aware of the importance of highly efficient nursing methods and are committed to applying relevant methods to practice.

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
49
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
132
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
65